We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
Read MoreHide Full Article
RedHill Biopharma (RDHL - Free Report) announced data from a preclinical in vivo study, evaluating its COVID-19 drug Opaganib in kidney inflammation and fibrosis. Data from the study demonstrated that Opaganib achieved efficacy in significantly reducing renal fibrosis in patients with chronic kidney disease (“CKD”) in a well characterized unilateral ureteral obstruction model.
Shares of RedHill have rallied 18.2% so far this year against the industry’s 9.6% decline.
Image Source: Zacks Investment Research
In CKD patients, renal fibrosis is a progressive process that may result in end-stage renal failure. COVID-19 and long COVID patients also have a high risk of kidney damage.
More than 20% of hospitalized COVID patients experience acute renal failure. Acute kidney injury –- a potential consequence of COVID-19 –- results in the inability of the kidneys to be repaired properly. Opaganib inhibits the sphingosine kinase-2, a key enzyme that is part of the process that prevents the kidney from repairing itself and replicating the COVID-19 virus.
It is to be noted that Opaganib, an oral pill drug candidate with dual anti-inflammatory and antiviral activity, is currently being evaluated in a phase II/III study in hospitalized patients with COVID-19. This study has completed treatment and follow up phase, with top-line results expected shortly.
The company recently announced positive preliminary results from a new preclinical study on Opaganib. The drug demonstrated strong inhibition of delta variant of the COVID virus in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date.
Ironwood’s earnings per share estimates for 2021 have increased from $1.00 to $1.18 in the past 60 days. The same for 2022 has risen from $1.18 to $1.72 over the same period. The stock has rallied 10.3% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $49.51 to $54.15 in the past 60 days. The same for 2022 has risen from $41.30 to $44.11 over the same period. The stock has rallied 38.4% in the year so far.
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 60 days. The same for 2022 has risen from $2.56 to $3.02 over the same period. The stock has rallied 54.6% in the year so far.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
RedHill Biopharma (RDHL - Free Report) announced data from a preclinical in vivo study, evaluating its COVID-19 drug Opaganib in kidney inflammation and fibrosis. Data from the study demonstrated that Opaganib achieved efficacy in significantly reducing renal fibrosis in patients with chronic kidney disease (“CKD”) in a well characterized unilateral ureteral obstruction model.
Shares of RedHill have rallied 18.2% so far this year against the industry’s 9.6% decline.
Image Source: Zacks Investment Research
In CKD patients, renal fibrosis is a progressive process that may result in end-stage renal failure. COVID-19 and long COVID patients also have a high risk of kidney damage.
More than 20% of hospitalized COVID patients experience acute renal failure. Acute kidney injury –- a potential consequence of COVID-19 –- results in the inability of the kidneys to be repaired properly. Opaganib inhibits the sphingosine kinase-2, a key enzyme that is part of the process that prevents the kidney from repairing itself and replicating the COVID-19 virus.
It is to be noted that Opaganib, an oral pill drug candidate with dual anti-inflammatory and antiviral activity, is currently being evaluated in a phase II/III study in hospitalized patients with COVID-19. This study has completed treatment and follow up phase, with top-line results expected shortly.
The company recently announced positive preliminary results from a new preclinical study on Opaganib. The drug demonstrated strong inhibition of delta variant of the COVID virus in a human bronchial epithelial cells model, adding to prior data demonstrating potent inhibition of all COVID-19 variants tested to date.
Redhill Biopharma Ltd. Price
Redhill Biopharma Ltd. price | Redhill Biopharma Ltd. Quote
Zacks Rank & Stocks to Consider
RedHill currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks in the biotech/drug sector include Ironwood Pharmaceuticals (IRWD - Free Report) , Regeneron Pharmaceuticals (REGN - Free Report) and Repligen Corporation (RGEN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Ironwood’s earnings per share estimates for 2021 have increased from $1.00 to $1.18 in the past 60 days. The same for 2022 has risen from $1.18 to $1.72 over the same period. The stock has rallied 10.3% in the year so far.
Regeneron’s earnings per share estimates for 2021 have increased from $49.51 to $54.15 in the past 60 days. The same for 2022 has risen from $41.30 to $44.11 over the same period. The stock has rallied 38.4% in the year so far.
Repligen’s earnings per share estimates for 2021 have increased from $2.26 to $2.76 in the past 60 days. The same for 2022 has risen from $2.56 to $3.02 over the same period. The stock has rallied 54.6% in the year so far.